Cumulative incidence of relapse. (A) Incidence of relapse by TCR status. Cumulative incidence of relapse is indicated in the 23, 29, and 29 CR patients with IM (solid line), pre-αβ (bold dotted line), and TCR⁺ ALL (thin dotted line), respectively. No significant difference was observed between these 3 subsets (P = .51 by the Gray test). (B) Incidence of relapse by genetic abnormalities. Cumulative incidence of relapse was higher in the 11 CR patients with SIL-TAL1⁺ ALL (thin dotted line; 82% at 4 years) and in the 6 CR patients with HOX11L2⁺ ALL (bold dotted line; 83% at 4 years) compared with the 54 other CR patients tested (solid line; 53% at 4 years) (P = .05 by the Gray test).